312 related articles for article (PubMed ID: 33207783)
41. Role of steroid sulfatase in local formation of estrogen in post-menopausal breast cancer patients.
Nakata T; Takashima S; Shiotsu Y; Murakata C; Ishida H; Akinaga S; Li PK; Sasano H; Suzuki T; Saeki T
J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):455-60. PubMed ID: 14623544
[TBL] [Abstract][Full Text] [Related]
42. Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?
Howell A; Howell SJ; Clarke R; Anderson E
J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):227-37. PubMed ID: 11850229
[TBL] [Abstract][Full Text] [Related]
43. Identification of Non-steroidal Aromatase Inhibitors via In silico and In vitro Studies.
Zafar H; Anis R; Hafeez S; Wahab AT; Khan MA; Basha FZ; Maslennikov I; Choudhary MI
Med Chem; 2023; 19(10):996-1001. PubMed ID: 37005533
[TBL] [Abstract][Full Text] [Related]
44. Estrogen-mediated mechanisms to control the growth and apoptosis of breast cancer cells: a translational research success story.
McDaniel RE; Maximov PY; Jordan VC
Vitam Horm; 2013; 93():1-49. PubMed ID: 23810002
[TBL] [Abstract][Full Text] [Related]
45. Steroid sulfatase inhibitors for estrogen- and androgen-dependent cancers.
Purohit A; Foster PA
J Endocrinol; 2012 Feb; 212(2):99-110. PubMed ID: 21859802
[TBL] [Abstract][Full Text] [Related]
46. Medicinal chemistry aspects and synthetic strategies of coumarin as aromatase inhibitors: an overview.
Ratre P; Kulkarni S; Das S; Liang C; Mishra PK; Thareja S
Med Oncol; 2022 Dec; 40(1):41. PubMed ID: 36471176
[TBL] [Abstract][Full Text] [Related]
47. Efficacy of a novel orally active SERD AZD9496 against hormone dependent post-menopausal breast cancer depends on inhibition of cellular aromatase activity.
Kazi A; Goloubeva O; Schech A; Yu S; Sabnis GJ
J Steroid Biochem Mol Biol; 2020 Sep; 202():105697. PubMed ID: 32461092
[TBL] [Abstract][Full Text] [Related]
48. Sex hormone receptors in breast cancer.
D'Abreo N; Hindenburg AA
Vitam Horm; 2013; 93():99-133. PubMed ID: 23810004
[TBL] [Abstract][Full Text] [Related]
49. Aromatase inhibitors for treatment of breast cancer: current concepts and new perspectives.
Santen RJ
Breast Cancer Res Treat; 1986; 7 Suppl():S23-35. PubMed ID: 3527304
[TBL] [Abstract][Full Text] [Related]
50. New aromatase inhibitors from the 3-pyridyl arylether and 1-aryl pyrrolo[2,3-c]pyridine series.
Stauffer F; Furet P; Floersheimer A; Lang M
Bioorg Med Chem Lett; 2012 Mar; 22(5):1860-3. PubMed ID: 22335894
[TBL] [Abstract][Full Text] [Related]
51. Adaptive hypersensitivity to estrogen: mechanism for superiority of aromatase inhibitors over selective estrogen receptor modulators for breast cancer treatment and prevention.
Santen RJ; Song RX; Zhang Z; Kumar R; Jeng MH; Masamura S; Yue W; Berstein L
Endocr Relat Cancer; 2003 Jun; 10(2):111-30. PubMed ID: 12790774
[TBL] [Abstract][Full Text] [Related]
52. [Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects].
de Cremoux P; Diéras V; Poupon MF; Magdelénat H; Sigal-Zafrani B; Fourquet A; Pierga JY
Bull Cancer; 2004 Dec; 91(12):917-27. PubMed ID: 15634633
[TBL] [Abstract][Full Text] [Related]
53. Aromatase and breast cancer.
Chen S
Front Biosci; 1998 Aug; 3():d922-33. PubMed ID: 9696881
[TBL] [Abstract][Full Text] [Related]
54. Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients.
Chanplakorn N; Chanplakorn P; Suzuki T; Ono K; Chan MS; Miki Y; Saji S; Ueno T; Toi M; Sasano H
Breast Cancer Res Treat; 2010 Apr; 120(3):639-48. PubMed ID: 20151319
[TBL] [Abstract][Full Text] [Related]
55. [Role for aromatase inhibitors as adjuvant treatment of breast cancer in menopaused women: facts and questions in 2005].
Lesur A; Cutuli B; Teissier MP; Luporsi E
J Gynecol Obstet Biol Reprod (Paris); 2006 Jun; 35(4):327-40. PubMed ID: 16940902
[TBL] [Abstract][Full Text] [Related]
56. Anti-tumor effect of Shu-Gan-Liang-Xue decoction in breast cancer is related to the inhibition of aromatase and steroid sulfatase expression.
Zhou N; Han SY; Zhou F; Li PP
J Ethnopharmacol; 2014 Jul; 154(3):687-95. PubMed ID: 24809288
[TBL] [Abstract][Full Text] [Related]
57. [Progress in study of the structure, catalytic mechanism and inhibitors of aromatase].
Fu J; Shen ZH; Cheng FX; Liu GX; Li WH; Tang Y
Yao Xue Xue Bao; 2012 Jan; 47(1):18-28. PubMed ID: 22493800
[TBL] [Abstract][Full Text] [Related]
58. Selective regulation of aromatase expression for drug discovery.
Brueggemeier RW; Su B; Darby MV; Sugimoto Y
J Steroid Biochem Mol Biol; 2010 Feb; 118(4-5):207-10. PubMed ID: 19931613
[TBL] [Abstract][Full Text] [Related]
59. Aromatase in breast cancer and the role of aminoglutethimide and other aromatase inhibitors.
Brodie AM; Santen RJ
Crit Rev Oncol Hematol; 1986; 5(4):361-96. PubMed ID: 3094971
[TBL] [Abstract][Full Text] [Related]
60. Estrogen signaling in cancer microenvironment and prediction of response to hormonal therapy.
Hayashi S; Yamaguchi Y
J Steroid Biochem Mol Biol; 2008 Apr; 109(3-5):201-6. PubMed ID: 18424035
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
